Grey Wolf Therapeutics
4 known investors
Greywell Therapeutics develops treatments that modulate antigen presentation to guide T cell recognition and targeting, addressing cancers, autoimmune disorders, and infectious diseases. The company has clinical-stage assets in oncology and autoimmunity advancing through Phase 1/2 trials.